Evidence map›Paper›PMID 39758250›Full record

ArticleMolecular therapy. Oncology2024

Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target.

Antonio J Montero-Hidalgo, Enrique Gómez-Gómez, Manuel Galán-Cañete, Francisco Porcel-Pastrana, Jesús M Pérez-Gómez, María Ortega-Bellido, Julia Carrasco-Valiente, Laura Chamorro-Castillo, Juan P Campos-Hernández, Oriol A Rangel-Zuñiga and 6 more

Abstract read
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Antonio J Montero-HidalgoMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Enrique Gómez-GómezMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Manuel Galán-CañeteMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Francisco Porcel-PastranaMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Jesús M Pérez-GómezMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
María Ortega-BellidoMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Julia Carrasco-ValienteMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Laura Chamorro-CastilloMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Juan P Campos-HernándezMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Oriol A Rangel-ZuñigaMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Teresa González-SerranoMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Rafael Sánchez-SánchezMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
André Sarmento-CabralMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Manuel D GaheteMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Juan M Jiménez-VacasMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.
Raúl M LuqueMaimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is the second most common cancer among men worldwide. The main screening tool remains the prostate-specific antigen (PSA), which shows significant limitations, including poor sensitivity/specificity. Therefore, establishing accurate non-invasive diagnostic biomarkers remains an unmet clinical need in PCa. In this context, the splicing process dysregulation represents a PCa hallmark. Here, plasma SRRM1, SNRNP200, and SRSF3 levels, previously identified to play a pathophysiological role in PCa, were determined in control individuals (

Indexed as

biomarkerMT: Novel therapeutic targets and biomarker development Special Issueprostate cancerSNRNP200SRRM1SRSF3therapeutic target

Identifiers

PMID39758250
PMCPMC11697196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.